Category: News

IRVINE, Calif., July 11, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the Compensation Committee of Reneo’s Board of Directors (the Compensation Committee) granted inducement awards to a non-executive new employee, consisting of… Continue reading Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., June 30, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that data from the Company’s Phase 1 leg immobilization study of REN001 in healthy volunteers has been accepted for presentation at the… Continue reading Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)

IRVINE, Calif., May 10, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended March 31, 2022. “During the first quarter of 2022, we continued to make good progress across… Continue reading Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results

IRVINE, Calif., March 23, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter and year ended December 31, 2021 and provided a business update. 2021 Highlights Raised gross proceeds of… Continue reading Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Michael P. Cruse appointed Chief Operating Officer Jennifer P. Lam appointed Principal Financial and Accounting Officer IRVINE, Calif., March 07, 2022 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the appointments of Michael P. Cruse… Continue reading Reneo Pharmaceuticals Announces Senior Leadership Promotions

IRVINE, Calif., Feb. 02, 2022 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will be hosting a fireside chat and participating in one-on-one investor meetings at SVB Leerink’s Virtual Global Healthcare Conference taking… Continue reading Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference

IRVINE, Calif., Jan. 24, 2022 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced changes to its Board of Directors. Paul W. Hoelscher, Executive Vice President, Chief Financial Officer of Horizon Therapeutics plc, has been appointed… Continue reading Reneo Pharmaceuticals Announces Changes to its Board of Directors

IRVINE, Calif., Nov. 11, 2021 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, today reported financial results for the quarter ended September 30, 2021 and provided an update on its clinical programs. “We continued to make good… Continue reading Reneo Pharmaceuticals Reports Third Quarter 2021 Financial Results

IRVINE, Calif., Nov. 01, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will be participating in the following investors conferences during the month of November. Conference and presentation details are as follows:… Continue reading Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

IRVINE, Calif., Oct. 14, 2021 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for patent application No. 17/381,005.… Continue reading Reneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001